Avadel Pharmaceuticals Showcases LUMRYZ™ at World Sleep 2025
Avadel Pharmaceuticals plc (NASDAQ: AVDL), a biopharmaceutical company committed to innovating treatments that change lives, announced an exciting presentation at World Sleep 2025. The event, taking place in Singapore, will feature the company showcasing vital research on LUMRYZ™, a once-nightly treatment for narcolepsy, encompassing one oral presentation and 16 poster presentations.
Dr. Gerard J. Meskill, CEO of Tricoastal Narcolepsy and Sleep Disorders Center, expressed enthusiasm over LUMRYZ’s unique once-nightly dosing, offering patients a hassle-free alternative to traditional treatments. This method alleviates the stress of waking at night for administration while ensuring that patients receive the therapeutic benefits throughout the entire night. The REFRESH study’s findings demonstrate significant improvements for those switching from a twice-nightly oxybate regimen, as well as for new patients.
Highlights from the REFRESH Study
The REFRESH study has provided meaningful insights that will be discussed at the upcoming conference. Key findings indicated that participants showed remarkable enhancements in their Epworth Sleepiness Scale (ESS) scores, dropping to the normal range, indicating reduced excessive daytime sleepiness (EDS). Furthermore, there was a notable decrease in symptoms measured by the Narcolepsy Severity Scale (NSS) from moderate to mild severity, reflecting a vast improvement in overall well-being among participants.
The data also revealed that a substantial majority of participants experienced positive outcomes after four months of treatment. Specifically, around 70% of switch participants and 90% of naïve participants reported improved conditions on standardized global scales. This transformation indicates the potential of LUMRYZ to significantly enhance the daily lives of those dealing with narcolepsy.
Comorbidities and Further Insights
A secondary analysis conducted at Duke University highlighted the common comorbidities faced by narcolepsy patients. The study compared data from nearly 1,700 narcolepsy patients with matched controls, revealing higher occurrences of psychiatric disorders, chronic pain, and sleep disturbances among those with narcolepsy. These insights stress the necessity of improved treatment options that address not just narcolepsy symptoms but associated challenges as well.
Jennifer Gudeman, Pharm.D. and Senior Vice President of Medical and Clinical Affairs at Avadel, remarked on the remarkable benefits of LUMRYZ demonstrated in research outcomes. She emphasized the effectiveness of LUMRYZ for both naïve patients and those switching from other oxybates, reinforcing its role in addressing complex narcolepsy symptoms.
Presentation Schedule at World Sleep 2025
The oral presentation scheduled for September 9 will focus on comparing the performance of LUMRYZ against standard treatments for daytime sleepiness among narcolepsy patients. Attendees can glean insights into how this innovative therapy aligns with broader treatment goals targeting reduced night-time interruptions.
Posters will cover diverse topics, including the impacts of once-nightly sodium oxybate on other sleep disorder metrics, providing a holistic view of the treatment's effectiveness. Presentations will include:
- Effects of Once-Nightly Sodium Oxybate on Apnea-Hypopnea Index
- Assessing Usability For Patients with Narcolepsy
- Comorbidities in Narcolepsy Patients: Insights from Patient Data
About LUMRYZ and Its Impact
LUMRYZ stands out as a pioneering extended-release sodium oxybate, approved for treating EDS and cataplexy in individuals with narcolepsy. The innovative formulation ensures that patients receive the necessary dosage in a singular administration at bedtime, making it a convenient option for both adult and pediatric patients aged seven and above.
With its FDA approvals, LUMRYZ secured seven years of Orphan Drug Exclusivity. Its introduction into the market has been supported by extensive clinical trial data that attests to its superior efficacy compared to traditional therapies. This accomplishment signifies a critical advancement in narcolepsy treatment, underscoring LUMRYZ’s potential to transform patient care.
Avadel’s deep commitment is not just to bring LUMRYZ to market but to ensure that this revolutionary treatment becomes accessible to those in need, ultimately aiming to enhance the quality of life for many.
Frequently Asked Questions
What is LUMRYZ and how does it work?
LUMRYZ is an extended-release medication aimed at treating narcolepsy's symptoms through a once-nightly dose, ensuring effective management without night-time interruptions.
What were the main findings from the REFRESH study?
Participants in the REFRESH study saw significant improvements in symptoms of excessive daytime sleepiness and overall narcolepsy severity after switching to LUMRYZ.
How is LUMRYZ administered?
LUMRYZ is taken as a single oral dose at bedtime, allowing patients to manage their symptoms with ease and convenience.
Who is eligible for LUMRYZ treatment?
LUMRYZ is approved for patients with narcolepsy aged seven years and older and is effective for both new patients and those switching from other oxybate medications.
Where can I find more information about Avadel Pharmaceuticals?
For additional information, visit Avadel Pharmaceuticals' official website at www.avadel.com.
